Medications development to treat alcohol dependence: A vision for the next decade

Addiction Biology

Volumn 17, Issue 3, 2012, Pages 513-527

  Litten, Raye Z ^a   Egli, Mark ^a   Heilig, Markus ^a   Cui, Changhai ^a   Fertig, Joanne B ^a   Ryan, Megan L ^a   Falk, Daniel E ^a   Moss, Howard ^a   Huebner, Robert ^a   Noronha, Antonio ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Alcohol; alcohol dependence; alcohol use disorders; drug development; medications

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; 1,2,3,4,4A,5,12,12AALPHA OCTAHYDRO 4AALPHA (3 HYDROXYPHENYL) 2 METHYLQUINOLINO[2,3 G]ISOQUINOLINE; 2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; 2,6 DI TERT BUTYL 4 (3 HYDROXY 2,2 DIMETHYLPROPYL)PHENOL; ACAMPROSATE; ANTALARMIN; APREPITANT; BACLOFEN; BHF 177; CEFTRIAXONE; CP 601932; CVT 10216; DULOXETINE; GABAPENTIN; IBUDILAST; IVERMECTIN; JNJ 10397049; LY 686017; MEMANTINE; MINOCYCLINE; N [2 [1,2 DIHYDRO 3,5(4H) DIOXO 1,2 DIPHENYL 1,2,4 TRIAZOL 4 YL]ETHYL] N2 [[1 [2 [4 [5,11 DIHYDRO 6(6H) OXODIBENZ[B,E]AZEPIN 11 YL] 1 PIPERAZINYL] 2 OXOETHYL]CYCLOPENTYL]ACETYL]ARGININAMIDE; N,N' DICYCLOPENTYL 2 METHYLTHIO 5 NITRO 4,6 PYRIMIDINEDIAMINE; NALMEFENE; NALTREXONE; NCG 0018568403; NELIVAPTAN; NERAMEXANE; NORIBOGAINE; OLANZAPINE; ONDANSETRON; ORG 25935; OS 462; PEXACERFONT; PIOGLITAZONE; PRAZOSIN; PREGABALIN; RAPAMYCIN; ROLIPRAM; RY 023; SORI 9409; TOPIRAMATE; TRICHOSTATIN A; UFP 102; UFP 112; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARENICLINE; VERUCERFONT; ZONISAMIDE;

3' UNTRANSLATED REGION; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; ALLELE; CLINICAL EVALUATION; CLINICAL TRIAL; DISEASE COURSE; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG INDUSTRY; DRUG MECHANISM; DRUG RESPONSE; ENVIRONMENTAL FACTOR; EXPERIMENTAL MODEL; GOVERNMENT; HEALTH CARE ORGANIZATION; HELP SEEKING BEHAVIOR; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; REVIEW; SEROTONINERGIC SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT;

ALCOHOLISM; ANIMALS; CENTRAL NERVOUS SYSTEM AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG APPROVAL; DRUG DISCOVERY; FORECASTING; HUMANS; INDIVIDUALIZED MEDICINE; PLACEBO EFFECT; TECHNOLOGY, PHARMACEUTICAL; TREATMENT OUTCOME;

EID: 84860229812     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2012.00454.x     Document Type: Review

References (115)

1. Agres T, Gwynne P, (2010) Remodeling pharma. In:, Abbate J, ed. Scientific American Pathways: 2010, pp. 66-76. New York: Scientific American.
2. Anton RF, Drobes DJ, Voronin K, Duraxo-Avizu R, Moak D, (2004) Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology (Berl) 173: 32-40.
3. Anton RF, Kranzler H, Breder C, Marcus RN, Carson WH, Han J, (2008) A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol 28: 5-12.
4. Anton RF, Litten RZ, Falk DE, Palumbo JM, Bartus RT, Robinson RL, Kranzler HR, Kosten TR, Meyer RE, O'Brien CP, Mann K, Meulien D, (2012) The Alcohol Clinical Trials Initiative (ACTIVE): purpose and goals for assessing important and salient issues for medications development alcohol use disorders. Neuropsychopharmacology 37: 402-411.
5. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A, (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence. JAMA 295: 2003-2017.
6. Barnett N, (2011) Symposium: new developments in research with transdermal alcohol sensors: laboratory, field, and clinical applications. 34th Annual Scientific Meeting of the Research Society on Alcoholism, Atlanta, GA.
7. Barr CS, Chen SA, Schwandt ML, Lindell SG, Sun H, Suomi SJ, Heilig M, (2010) Suppression of alcohol preference by naltrexone in the Rhesus Macaque: a critical role of genetic variation at the μ-opioid receptor gene locus. Biol Psychiatry 67: 78-80.
8. Barr CS, Schwandt M, Lindell SG, Chen SA, Goldman D, Suomi SJ, Higley D, Heilig M, (2007) Association of a functional polymorphism in the μ-opioid receptor gene with alcohol response and consumption in male Rhesus Macaques. Arch Gen Psychiatry 64: 369-376.
9. Barron S, Littleton J, (in press) Polyamines and the NMDA receptor in medications development for alcohol abuse/dependence. Recent Pat CNS Drug Discov.
10. Becker HC, Lopez MF, (2004) Increased ethanol drinking after repeated chronic ethanol exposure and withdrawal experience in C57BL/6 mice. Alcohol Clin Exp Res 28: 1829-1838.
11. Benedetti F, Mayberg HS, Wager TD, Stohler CS, Zubieta JK, (2005) Neurobiological mechanisms of the placebo effect. J Neurosci 25: 10390-10402.
12. Breslow RA, Graubard BI, (2008) Prospective study of alcohol consumption in the United States: quantity, frequency, and cause-specific mortality. Alcohol Clin Exp Res 32: 513-521.
13. Burrill GS, (2010) Healthcare on the threshold of innovation. In:, Abbate J, ed. Scientific American Pathways: 2010, pp. 18-19. New York: Scientific American.
14. Chaplin TM, Hong K, Bergquist K, Sinha R, (2008) Gender differences in response to emotional stress: an assessment across subjective, behavioral, and physiological domains and relations to alcohol craving. Alcohol Clin Exp Res 32: 1242-1250.
15. Collins FS, (2011) Reengineering translational science: the time is right. Sci Translat Med 3: 1-6.
16. Crabbe JC, Bell RL, Ehlers CL, (2010) Human and laboratory rodent low response to alcohol: is better consilience possible? Addict Biol 15: 125-144.
17. Dawson DA, Li TK, Grant BF, (2008) A prospective study of risk drinking: at risk for what? Drug Alcohol Depend 95: 62-72.
18. Egli M, (2005) Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism? Addict Biol 10: 309-319.
19. Falk D, Wang XQ, Liu L, Fertig J, Mattson M, Ryan M, Johnson B, Stout R, Litten RZ, (2010) Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials. Alcohol Clin Exp Res 34: 2022-2034.
20. Farrar JT, Dworkin RH, Mitchell BM, (2006) Use of the cumulative proportion of responders analysis graph to present pain data over a range of cut-off points: making clinical trial data more understandable. J Pain Symptom Manage 31: 369-377.
21. FDA (2004) Challenge and Opportunity on the Critical Path to New Medical Products. Rockville, MD: US Department of Health and Human Services.
22. FDA (2006a) Critical Path Opportunities Report. Rockville, MD: US Department of Health and Human Services.
23. FDA (2006b) Medical Review of Vivitrol: 21-897. Rockville, MD: US Department of Health and Human Services.
24. Finniss DG, Kaptchuk TJ, Miller F, Benedetti F, (2010) Biological, clinical, and ethical advances of placebo effects. Lancet 375: 686-695.
25. Gelernter J, Gueorguieva P, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH, (2007) Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res 31: 555-563.
26. George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C, Peng X, Kielbasa W, Rawlings R, Brandt JE, Gehlert DR, Tauscher JT, Hunt SP, Hommer D, Heilig M, (2008) Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 319: 1536-1539.
27. George O, Koob GF, (2010) Individual differences in prefrontal cortex function and the transition from drug use to drug dependence. Neurosci Biobehav Rev 35: 232-247.
28. Gorelick DA, (1989) Serotonin uptake blockers and the treatment of alcoholism. In:, Galanter M, ed. Recent Developments in Alcoholism: Treatment, Vol. 7, pp. 267-281. New York: Plenum Press.
29. Grant BF, Dawson DA, Stinson FS, Chou SP, Dufour MC, Pickering RP, (2004) The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend 74: 223-234.
30. Greenfield TM, Bond J, Kerr WC, Nayak MB, Anton RF, Kranzler HR, Kaskutas LA, (2005) Risks of alcohol use disorders for treated and concerned individuals are higher than for others at given patterns of drinking. Presented at Annual Epidemiological Symposium of the Kettil Bruun Society for the Epidemiological and Social Research on Alcohol, Riverside, CA, May 30.
31. Griffin WC, Lopez MF, Yanke AB, Middaugh LD, Becker HC, (2009) Repeated cycles of chronic intermittent ethanol exposure in mice increases voluntary ethanol drinking and ethanol concentrations in the nucleus accumbens. Psychopharmacology (Berl) 201: 569-580.
32. Haber SN, Rauch SL, (2010) Neurocircuitry: a window into the networks underlying neuropsychiatric disease. Neuropsychopharmacology 35: 1-3.
33. Heilig M, Egli M, (2006) Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther 111: 855-876.
34. Heilig M, Egli M, Crabbe JC, Becker HC, (2010) Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked? Addict Biol 15: 169-184.
35. Heilig M, Goldman D, Berrettini W, O'Brien CP, (2011) Pharmacogenetic approaches to the treatment of alcohol addiction. Nat Rev Neurosci 12: 670-684.
36. Heilig M, Koob GF, (2007) A key role for corticotrophin-releasing factor in alcohol dependence. Trends Neurosci 30: 399-406.
37. Hopkins AL, (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4: 682-6690.
38. Hurko O, Ryan JL, (2005) Translational research in central nervous system drug discovery. NeuroRx 2: 671-682.
39. Hutchison KE, (2010) Substance use disorders: realizing the promise of pharmacogenomics and personalized medicine. Annu Rev Clin Psychol 6: 577-589.
40. Hutchison KE, Ray L, Sandman E, Rutter MC, Peters A, Davidson D, Swift R, (2006) The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology 31: 1310-1317.
41. Insel TR, (2010) Faulty circuits. Sci Am 302: 44-51.
42. Jackson KM, (2008) Heavy episodic drinking: determining the predictive utility of five or more drinks. Psychol Addict Behav 22: 68-77.
43. Johnson BA, (2008) Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol 75: 34-56.
44. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, (2003) Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet 361: 1677-1685.
45. Johnson BA, Ait-Daoud N, Seneviratne C, Roache JD, Javors MA, Wang XQ, Liu L, Penberthy JK, DiClemente CC, Li MD, (2011) Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry 168: 265-275.
46. Johnson BA, Jasinski DR, Galloway GP, Kranzler H, Weinreib R, Anton RF, Mason BJ, Bohn MJ, Pettinati HM, Rawson R, Clyde C, (1996) Ritanserin in the treatment of alcohol dependence-a multi-center clinical trial. Psychopharmacology (Berl) 128: 206-215.
47. Johnson BA, Mann K, Willenbring ML, Litten RZ, Swift RM, Lesch OM, Berglund M, (2005) Challenges and opportunities for medications development in alcoholism: an international perspective on collaborations between academia and industry. Alcohol Clin Exp Res 29: 1528-1540.
48. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM, (2007) Topiramate for treating alcohol dependence. JAMA 298: 1641-1651.
49. Kaitin KI, Milne CP, (2011) A dearth of new meds. Sci Am 305: 16.
50. Kaptchuk T, Kelley JM, Conboy LA, Davis RB, Kerr CE, Jacobson EE, Kirsch I, Schyner RN, Nam BH, Nguyen LT, Park M, Rivers AL, McManus C, Kokkotou E, Drossman DA, Goldman P, Lembo AJ, (2008) Components of placebo effect: randomized controlled trial in patients with irritable bowel syndrome. BMJ 336: 999-1003.
51. Kendler KS, (2005) Toward a philosophical structure for psychiatry. Am J Psychiatry 162: 433-440.
52. Kiefer F, Witt SH, Frank J, Richter A, Treutlein J, Lemenager T, Nothen MM, Cichon S, Batra A, Berner M, Wodarz N, Zimmermann US, Spanagel R, Wiedermann K, Smolka MN, Heinz A, Rietschel M, Mann K, (2011) Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. Pharmacogenomics J 11: 368-374.
53. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT, (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5: 260-268.
54. Knudsen HK, Abraham AJ, Roman PM, (2011) Adoption and implementation of medications in addiction treatment programs. J Addict Med 5: 21-27.
55. Koob GF, Bloom FE, (1988) Cellular and molecular mechanisms of drug dependence. Science 242: 715-723.
56. Koob GF, Lloyd GK, Mason BJ, (2009) Development of pharmacotherapies for drug addiction: a Rosetta Stone approach. Nat Rev Drug Discov 8: 500-515.
57. Koob GF, Volkow ND, (2009) Neurocircuitry of addiction. Neuropsychopharmacology 35: 217-238.
58. Kranzler HR, Armeli S, Tennen H, Covault J, Feinn R, Arias A, Pettinati H, Oncken C, (2011) A double-blind, randomized trial of sertraline for alcohol dependence. J Clin Psychopharmacol 31: 22-30.
59. Kranzler HR, Edenberg HJ, (2010) Pharmacogenetics of alcohol and alcohol dependence treatment. Curr Pharm Des 16: 2141-2148.
60. 1 receptor antagonists. Trends Pharmacol Sci 32: 270-280.
61. Leeman RF, Heilig M, Cunningham CL, Stephens DN, Duka T, O'Malley SS, (2010) Ethanol consumption: how should we measure it? Achieving consilience between human and animal phenotypes. Addict Biol 15: 109-124.
62. Li TK, (2007) Quantifying the risk for alcohol-use and alcohol-attributable health disorders: present findings and future research needs. J Gastroenterol Hepatol 23 (Suppl 1): S2-S8.
63. Li TK, Lumeng L, Doolittle DP, (1993) Selective breeding for alcohol preference and associated responses. Behav Genet 23: 163-170.
64. Li TK, Lumeng L, McBride WJ, Murphy JM, (1987) Rodent lines selected for factors affecting alcohol consumption. Alcohol Alcohol 1: 91-96.
65. Litten RZ, Allen JP, (1991) Pharmacotherapies for alcoholism: promising agents and clinical issues. Alcohol Clin Exp Res 15: 620-633.
66. Litten RZ, Bradley AM, Moss HB, (2010) Alcohol biomarkers in applied settings: recent advances and future research opportunities. Alcohol Clin Exp Res 34: 955-967.
67. Litten RZ, Fertig J, Falk DE, Ryan ML, Mattson ME, Collins JF, Murtaugh C, Ciraulo D, Green AI, Johnson B, Pettinati H, Swift R, Afshar M, Brunette MF, Tiouririne NAD, Kampman K, Stout R, (2012) A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res 36: 406-416.
68. Litten RZ, Fertig J, Mattson ME, Egli M, (2005) Development of medications for alcohol use disorders: recent advances and ongoing challenges. Expert Opin Emerg Drugs 10: 323-343.
69. Lopez MF, Becker HC, (2005) Effect of pattern and number of chronic ethanol exposures on subsequent voluntary ethanol intake in C57BL/6J mice. Psychopharmacology (Berl) 181: 688-696.
70. Mark TL, Kassed CA, Vandivort-Warren R, Levit KR, Kranzler HR, (2009) Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend 99: 345-349.
71. Mark TL, Kranzler HR, Song X, (2003a) Understanding US addiction physicians' low rate of naltrexone prescription. Drug Alcohol Depend 71: 219-228.
72. Mark TL, Kranzler HR, Song X, Bransberger P, Poole VH, Crosse S, (2003b) Physicians' opinions about medications to treat alcoholism. Addiction 98: 617-626.
73. Mason BJ, Light JM, Escher T, Drobes DJ, (2008) Effect of positive and negative affective stimuli and beverage cues on measures of craving in non treatment-seeking alcoholics. Psychopharmacology (Berl) 200: 141-150.
74. McCoy JG, Marugan JJ, Liu K, Zheng W, Southall N, Huang W, Heilig M, Austin CP, (2010) Selective modulation of Gq/Gs pathways by naphtha pyrano pyrimidines as antagonists of the neuropeptide S receptor. ACS Chem Neurosci 1: 559-574.
75. McLellan AT, (2007) Reducing heavy drinking: a public health strategy and a treatment goal? J Subst Abuse Treat 33: 81-83.
76. Mello NK, (1992) Behavioral strategies for the evaluation of new pharmacotherapies for drug abuse treatment. In:, Harris LS, ed. Problems of Drug Dependence 1991. DHHS(ADM) 92-1888, pp. 150-154. Washington, DC: US Government Printing Office.
77. Michaud CM, McKenna MT, Begg S, Tomijima N, Majmudar M, Bulzacchelli MT, Ebrahim S, Ezzati M, Salomon JA, Kreiser JG, Hogan M, Murray CJL, (2006) The burden of disease and injury in the United States 1996. Popul Health Metr 4: 1-49.
78. Miller G, (2010) Is pharma running out of brainy ideas? Science 329: 502-504.
79. Miranda R, MacKillop J, Monit PM, Rohsenow DJ, Tidey J, Gwaltney C, Swift R, Ray L, McGeary J, (2008) Effected of topiramate on urge to drink and the subject effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res 32: 489-497.
80. Mokdad AH, Marks JS, Stroup DF, Gerberding JL, (2004) Actual causes of death in the United States. JAMA 291: 1238-1245.
81. Munos B, (2009) Lessons from 60 years of pharmaceutical innovation. Nat Rev 8: 959-968.
82. Munos BH, Chin WW, (2009) A call for sharing: adapting pharmaceutical research to new realities. Sci Translat Med 1: 1-4.
83. Munos BH, Chin WW, (2011) How to revive breakthrough innovation in the pharmaceutical industry. Sci Translat Med 3: 1-3.
84. Naranjo CA, Dongier M, Bremner KE, (1997) Long-acting injectable bromocriptine does not reduce relapse in alcoholics. Addiction 92: 969-978.
85. Ningaraj NS, Chen W, Schloss JV, Faiman MD, Wu JY, (2001) S-methyl-N,N-diethylthiocarbamate sulfoxide elicits neuroprotective effect against N-methyl-D-aspartate receptor-medicated neurotoxicity. J Biomed Sci 8: 104-113.
86. Nunes EV, Levin FR, (2004) Treatment of depression in patients with alcohol or other drug dependence. JAMA 291: 1887-1896.
87. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ, (2002) Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary- adrenocortical axis. Psychopharmacology (Berl) 160: 19-29.
88. O'Malley SS, O'Connor PG, (2011) Medications for unhealthy alcohol use. Alcohol Res Health 33: 300-312.
89. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP, (2003) A functional polymorphism of the μ-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28: 1546-1552.
90. Overstreet DH, Kralic JE, Morrow AL, Ma ZZ, Zhang YW, Lee DYW, (2003) NPI-031G (puerarin) reduces anxiogenic effects of alcohol withdrawal or benzodiazepine inverse or 5-HT2c agonists. Pharmacol Biochem Behav 75: 619-625.
91. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL, (2010) How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev 9: 203-214.
92. Perkins KA, Lerman C, Stitzer ML, Fonte CA, Briski JL, Scott JA, Chengappa KNR, (2008) Development of procedures from early screening of smoking cessation medications in humans. Clin Pharmacol Ther 84: 216-221.
93. Powell BJ, Campbell JL, Landon JF, Liskow BI, Thomas HM, Nickel EJ, Dale TM, Penick EC, Samuelson SD, Lacoursiere RB, (1995) A double-blind, placebo-controlled study of nortriptyline, and bromocriptine in male alcoholics subtyped by comorbid psychiatric disorders. Alcohol Clin Exp Res 19: 462-468.
94. Project MATCH Research Group (1997) Matching alcoholism treatments to client heterogeneity: project MATCH posttreatment drinking outcomes. J Stud Alcohol 58: 7-29.
95. Ramchandani VA, O'Connor S, Neumark Y, Zimmermann US, Morzorati SL, de Wit H, (2006) The alcohol clamp: applications, challenges, and new directions-an RSA 2004 Symposium summary. Alcohol Clin Exp Res 30: 155-164.
96. Ramchandani VA, Umhau J, Pavon FJ, Ruiz-Velasco V, Margas W, Sun H, Damadzic R, Eskay R, Schoor M, Thorsell A, Schwandt ML, Sommer WH, George DT, Parsons LH, Herscovitch P, Hommer D, Heilig M, (2011) A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry 16: 809-817.
97. Ray LA, Hutchison KE, (2004) A polymorphism of the μ-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 28: 1789-1795.
98. Ray LA, Hutchison KE, (2007) Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response. Arch Gen Psychiatry 64: 1069-1077.
99. Ray LA, Miranda R, MacKillop J, McGeary J, Tidey JW, Rohsenow DJ, Gwaltney C, Swift RW, Monti PM, (2009) A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol 17: 122-129.
100. Redish AD, Jensen S, Johnson A, (2008) A unified framework for addiction: vulnerabilities in the decision process. Behav Brain Sci 31: 415-487.
101. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J, (2009) Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 373: 2223-2233.
102. Rimondini R, Arlinde C, Sommer W, Heilig M, (2002) Long-lasting increase in voluntary ethanol consumption and transcriptional regulation in the rat brain after intermittent exposure to alcohol. FASEB J 16: 27-35.
103. Roache JD, (2010) Role of the human laboratory in the development of medications for alcohol and drug dependence. In:, Johnson BA, ed. Addiction Medicine: Science and Practice, pp. 129-157. New York: Springer Science + Business Media.
104. Roberts AJ, Heyser C, Cole M, Griffin P, Koob GF, (2000) Excessive ethanol drinking following a history of dependence: animal model of allostasis. Neuropsychopharmacology 22: 581-594.
105. Roth BL, Sheffler DJ, Kroeze KWK, (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3: 353-359.
106. Schadt EE, (2010) Mastering information for personal medicine. In:, Abbate J, ed. Scientific American Pathways: 2010, pp. 64-65. New York: Scientific American.
107. Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R, (2009) Primary care validation of a single-question alcohol screening test. J Gen Intern Med 24: 783-788.
108. Spanagel R, (2009) Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev 89: 649-705.
109. Stephens DN, Duka T, Crombag HS, Cunningham CL, Heilig M, Crabbe JC, (2010) Reward sensitivity: issues of measurement, and achieving consilience between human and animal phenotypes. Addict Biol 15: 145-168.
110. Thomas CP, Wallack SS, Lee S, McCarty D, Swift R, (2003) Research to practice: adoption of naltrexone in alcoholism treatment. J Subst Abuse Treat 24: 1-11.
111. Thomas SE, Miller PM, Randall PK, Book SW, (2008) Improving acceptance of naltrexone in community addiction treatment centers: a pilot study. J Subst Abuse Treat 35: 260-268.
112. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R, (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358: 252-260.
113. + channels by the novel antiepileptic compound DCUKA: identification of the diphenylureido moiety as an inactivation modifier. Exp Neurol 178: 129-138.
114. Weiss RD, O'Malley SS, Hosking JD, LoCastro JS, Swift R, (2008) Do patients with alcohol dependence respond to placebo? Results from the COMBINE study. J Stud Alcohol Drugs 69: 878-884.
115. World Health Organization (2004) Global Status Report on Alcohol 2004. Geneva: WHO.